4,365 reports of this reaction
3.9% of all CABOZANTINIB reports
#5 most reported adverse reaction
DECREASED APPETITE is the #5 most commonly reported adverse reaction for CABOZANTINIB, manufactured by Exelixis, Inc.. There are 4,365 FDA adverse event reports linking CABOZANTINIB to DECREASED APPETITE. This represents approximately 3.9% of all 112,838 adverse event reports for this drug.
Patients taking CABOZANTINIB who experience decreased appetite should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DECREASED APPETITE is moderately reported among CABOZANTINIB users, representing a notable but not dominant share of adverse events.
In addition to decreased appetite, the following adverse reactions have been reported for CABOZANTINIB:
The following drugs have also been linked to decreased appetite in FDA adverse event reports:
DECREASED APPETITE has been reported as an adverse event in 4,365 FDA reports for CABOZANTINIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
DECREASED APPETITE accounts for approximately 3.9% of all adverse event reports for CABOZANTINIB, making it a notable side effect.
If you experience decreased appetite while taking CABOZANTINIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.